GlassScriptPhysician profile
Lacey Hough
NPI 1437634714
$2,733.50
in general payments reported to CMS, 2019-2025
27 companies · $724 in 2025
The $724 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $698 · 2022: $479 · 2023: $396 · 2024: $437 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $455.87 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $378.01 | 2022-2025 | Krystexxa, Evenity, Prolia |
| Pfizer INC. | $371.02 | 2021-2025 | |
| Lilly USA, LLC | $253.52 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $186.45 | 2021-2025 | |
| Glaxosmithkline, LLC. | $184.90 | 2021-2025 | Trelegy Ellipta |
| Horizon Therapeutics Plc | $183.35 | 2023 | Krystexxa |
| Amarin Pharma, INC. | $119.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $65.65 | 2021-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Biogen, INC. | $59.67 | 2021 | |
| Mylan Specialty L.P. | $58.40 | 2021-2024 | Yupelri |
| Exact Sciences Corporation | $51.84 | 2023-2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $45.14 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.04 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $32.74 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $27.51 | 2022 | |
| Sumitomo Pharma America, INC. | $26.38 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.06 | 2022-2025 | Jardiance |
| Astellas Pharma US INC | $22.79 | 2025 | Veozah |
| Eisai INC. | $22.07 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $20.53 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.13 | 2024 | |
| Nabriva Therapeutics, Plc | $19.30 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.78 | 2022 | |
| Medtronic, INC. | $16.17 | 2023 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $15.95 | 2024 | Airsupra |
| Alexion Pharmaceuticals, INC. | $15.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Hough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.